文献速递基础与转化研究临床试验与 GCP

抑制丙酮酸脱氢酶激酶改善遗传易感肺动脉高压患者的病情

Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients.
PubMed 文献 · Sci Transl Med · 2017-01-01

在人类肺动脉高压(PAH)肺组织中丙酮酸脱氢酶激酶(PDK)表达增加,离体使用PDK抑制剂二氯乙酸(DCA)可激活PDH并增加线粒体呼吸。一项为期4个月、开放标签研究显示,已接受获批iPAH治疗的iPAH患者使用DCA(3至6.25 mg/kg,每日两次)后平均肺动脉压和肺血管阻力降低、功能能力改善,但个体反应存在差异;离体和临床反应缺失与SIRT3和UCP2功能变异相关。

要点

  • 人类PAH肺组织PDK表达较健康肺增加,离体DCA可激活PDH并增加线粒体呼吸。
  • 4个月开放标签研究中,DCA(3至6.25 mg/kg,每日两次)使已接受获批iPAH治疗的iPAH患者平均肺动脉压和肺血管阻力降低、功能能力改善。
  • 离体和临床反应缺失与SIRT3和UCP2功能变异相关,该变异预测蛋白功能降低。

核心结论

  • 首次在人体开展针对线粒体的药物治疗iPAH的试验表明,PDK是可成药靶点,可在遗传易感患者中带来血流动力学改善,为精准医学方法铺路。

研究设计与样本

  • 4个月、开放标签研究,纳入已接受获批iPAH治疗的特发性PAH(iPAH)患者,给予DCA 3至6.25 mg/kg每日两次。
  • 离体研究使用移植的人PAH肺组织,以DCA处理激活PDH并增加线粒体呼吸。
  • 小鼠实验显示SIRT3和UCP2功能受损导致不依赖PDK的线粒体抑制和肺动脉高压。

主要发现

  • 与健康肺相比,人PAH的肺动脉中PDK增加。
  • 离体DCA处理人PAH肺组织可激活PDH并增加线粒体呼吸。
  • 临床研究中DCA导致平均肺动脉压和肺血管阻力降低、功能能力改善,但个体反应存在差异。
  • 离体和临床反应缺失与SIRT3和UCP2功能变异相关,该变异预测蛋白功能降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pulmonary arterial hypertension (PAH) is a progressive vascular disease with a high mortality rate. It is characterized by an occlusive vascular remodeling due to a pro-proliferative and antiapoptotic environment in the wall of resistance pulmonary arteries (PAs). Proliferating cells exhibit a cancer-like metabolic switch where mitochondrial glucose oxidation is suppressed, whereas glycolysis is up-regulated as the major source of adenosine triphosphate production. This multifactorial mitochondrial suppression leads to inhibition of apoptosis and downstream signaling promoting proliferation. We report an increase in pyruvate dehydrogenase kinase (PDK), an inhibitor of the mitochondrial enzyme pyruvate dehydrogenase (PDH, the gatekeeping enzyme of glucose oxidation) in the PAs of human PAH compared to healthy lungs. Treatment of explanted human PAH lungs with the PDK inhibitor dichloroacetate (DCA) ex vivo activated PDH and increased mitochondrial respiration. In a 4-month, open-label study, DCA (3 to 6.25 mg/kg b.i.d.) administered to patients with idiopathic PAH (iPAH) already on approved iPAH therapies led to reduction in mean PA pressure and pulmonary vascular resistance and improvement in functional capacity, but with a range of individual responses. Lack of ex vivo and clinical response was associated with the presence of functional variants of SIRT3 and UCP2 that predict reduced protein function. Impaired function of these proteins causes PDK-independent mitochondrial suppression and pulmonary hypertension in mice. This first-in-human trial of a mitochondria-targeting drug in iPAH demonstrates that PDK is a druggable target and offers hemodynamic improvement in genetically susceptible patients, paving the way for novel precision medicine approaches in this disease.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Michelakis ED, Gurtu V, Webster L, et al. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci Transl Med. 2017. PMID: 29070699. doi:10.1126/scitranslmed.aao4583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。